Recently, however, two highly selective inhibitors targeting the NLRP3–ASC–caspase-1–IL-1β/IL-18 axis have emerged, holding significant promise for treating NLRP3-driven diseases, including LN and other autoimmune conditions. This evidence concerns the gene CASP1 and lobular neoplasia.